Başkent Üniversitesi Yayınları

Permanent URI for this communityhttps://hdl.handle.net/11727/13092

Browse

Author: search.filters.author.Ersoy, AlparslanSubject: search.filters.subject.Complication

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Isolated Ocular Surface Squamous Neoplasia in a Renal Transplant Recipient
    (Başkent Üniversitesi, 2012-10) Aktas, Nimet; Aytac, Berna; Kilic, Nurten; Yazici, Bulent; Ersoy, Alparslan
    Ocular surface squamous neoplasia is a rare complication after a kidney transplant, related with increased risk and poor prognosis. Generally, ocular surface squamous neoplasia in kidney transplant patients is associated with skin lesions. We report a case of ocular surface squamous neoplasia without skin lesions in a kidney transplant recipient. Systematic periodic ophthalmic evaluation of recipients may help ensure the early diagnosis of subtle ocular surface squamous neoplasia.
  • No Thumbnail Available
    Item
    Everolimus-induced Lymphedema in a Renal Transplant Recipient: A Case Report
    (Başkent Üniversitesi, 2012-06) Ersoy, Alparslan; Koca, Nizameddin
    The mammalian target of rapamycin inhibitors is commonly preferred for solid organs for trans­plantation. Although these drugs have various adverse effects, sirolimus-related lymphedema has been rarely reported. We report a case of lymphedema related to everolimus after a kidney transplant. A 60-year-old woman successfully received a deceased-donor kidney. Everolimus was added to the treatment in postoperative month 3 owing to other immunosuppressive drugs’ adverse effects. Edema occurred first on her feet in the first year after the transplant. During 3 months’ follow-up, with no immunosuppressive adjustment, the edema progressed. Diagnosis of lymphedema was established. Several weeks after discontinuing everolimus, the patient’s lymphedema began to resolve itself and completely disappeared in 3 months. The mammalian target of rapamycin inhibitors rarely causes lymphedema by inhibiting different subtypes of vascular endothelial growth factors, which results in impaired lymphangiogenesis. While there are few reports about sirolimus-related lymphedema, this case represents the first everolimus-related case of lymphedema. Further studies are warranted to explain the underlying mechanisms.